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Abstract: OBJECTIVES The aim of this study was to evaluate the feasibility of a computed tomography
(CT) protocol enabling the visualization of the prostatic artery (PA) before prostatic artery embolization
(PAE) in benign prostatic hyperplasia, which provides quantitative perfusion information of the prostate
gland. MATERIALS AND METHODS In this institutional review board-approved study, 22 consecutive
patients (mean age, 67 ± 7 years) who were planned to undergo PAE underwent a dynamic CT scan of
the pelvis (scan range, 22.4 cm; cycle time, 1.5 seconds; scan time, 44 seconds; 25 scan cycles; 70 kVp;
100 mAs) after the administration of 70 mL of iodinated contrast media (flow rate, 6 mL/s; 10 seconds’
delay). Image postprocessing consisted of a spatiotemporal, frequency-depending multiband filtering
technique with noise reduction, motion correction, resulting in (1) time-resolved, temporal maximum
intensity projection (MIP) images from fusion of multiple arterial time points; (2) 4-dimensional (4D)
CT angiography images after bone and calcium plaque removal; and (3) parametric perfusion maps
of the prostate. Intraprocedural cone-beam CT was performed with a microcatheter in the PA. In
both modalities, the contrast-to-noise ratio of the right internal iliac artery or the PA was calculated,
respectively. Visibility of the PA was scored using a Likert scale (score 1 = not seen, to score 4 =
intraprostatic PA branches seen). Quantitative perfusion analysis of the dynamic pelvic CT included
calculation of the blood flow, blood volume, mean transit time, and flow extraction product. RESULTS
The average volume CT dose index and dose length product of CT was 35.7 ± 6.8 mGy and 737.4 ±
146.3 mGy·cm, respectively. Contrast-to-noise ratio of the pelvic vessels on temporal MIP images and
cone-beam CT were 45 ± 19 and 69 ± 27, respectively (P < 0.01). The mean visibility score of the
PA was 3.6 ± 0.6 for 4D-CT angiography and 3.97 ± 0.2 for cone-beam CT (P < 0.001). The PA
was visualized in 100% of 4D-CT angiography examinations, with one PA being visible only proximally.
Prostate CT perfusion analysis showed blood flow, blood volume, mean transit time, and flow extraction
product values of 27.9 ± 12.5 mL/100 mL/min, 2.0 ± 0.8 mL/100 mL, 4.5 ± 0.5 second, and 12.6 ± 5.4
mL/100 mL/min, respectively, for the whole prostate gland. About half the patients showed a pronounced
difference between the lobes. CONCLUSIONS We introduced a CT protocol for PAE planning providing
excellent visualization of the PA on temporal MIP images and 4D-CT angiography at a reasonable dose
and low contrast volume. In addition, quantitative perfusion information is available, which might be
useful for outcome prediction after embolization.
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Objectives: The aim of this study was to evaluate the feasibility of a computed
tomography (CT) protocol enabling the visualization of the prostatic artery (PA)
before prostatic artery embolization (PAE) in benign prostatic hyperplasia, which
provides quantitative perfusion information of the prostate gland.
Materials and Methods: In this institutional review board–approved study, 22
consecutive patients (mean age, 67 ± 7 years) who were planned to undergo
PAE underwent a dynamic CT scan of the pelvis (scan range, 22.4 cm; cycle time,
1.5 seconds; scan time, 44 seconds; 25 scan cycles; 70 kVp; 100 mAs) after the
administration of 70mL of iodinated contrast media (flow rate, 6mL/s; 10 seconds'
delay). Image postprocessing consisted of a spatiotemporal, frequency-depending
multiband filtering technique with noise reduction, motion correction, resulting
in (1) time-resolved, temporal maximum intensity projection (MIP) images from
fusion of multiple arterial time points; (2) 4-dimensional (4D) CT angiography
images after bone and calcium plaque removal; and (3) parametric perfusion
maps of the prostate. Intraprocedural cone-beam CT was performed with a
microcatheter in the PA. In both modalities, the contrast-to-noise ratio of the right
internal iliac artery or the PAwas calculated, respectively. Visibility of the PAwas
scored using a Likert scale (score 1 = not seen, to score 4 = intraprostatic PA
branches seen). Quantitative perfusion analysis of the dynamic pelvic CT in-
cluded calculation of the blood flow, blood volume, mean transit time, and flow
extraction product.
Results: The average volume CT dose index and dose length product of CTwas
35.7 ± 6.8 mGy and 737.4 ± 146.3 mGy·cm, respectively. Contrast-to-noise ratio
of the pelvic vessels on temporal MIP images and cone-beam CTwere 45 ± 19
and 69 ± 27, respectively (P < 0.01). The mean visibility score of the PA was
3.6 ± 0.6 for 4D-CT angiography and 3.97 ± 0.2 for cone-beam CT
(P < 0.001). The PA was visualized in 100% of 4D-CT angiography examina-
tions, with one PA being visible only proximally. Prostate CT perfusion analysis
showed blood flow, blood volume, mean transit time, and flow extraction product
values of 27.9 ± 12.5 mL/100 mL/min, 2.0 ± 0.8 mL/100 mL, 4.5 ± 0.5 second,
and 12.6 ± 5.4 mL/100 mL/min, respectively, for thewhole prostate gland. About
half the patients showed a pronounced difference between the lobes.
Conclusions:We introduced a CT protocol for PAE planning providing excellent
visualization of the PA on temporalMIP images and 4D-CTangiography at a reason-
able dose and low contrast volume. In addition, quantitative perfusion information
is available, which might be useful for outcome prediction after embolization.
Key Words: computed tomography, perfusion, angiography, prostate,
embolization
(Invest Radiol 2019;00: 00–00)
B enign prostatic hyperplasia (BPH) is a common disease of the olderman with, after conservative treatment failure, transurethral resection
of the prostate being the criterion standard treatment. Nevertheless, selec-
tive prostatic artery embolization (PAE) emerges as a minimally invasive
treatment alternative. A positive effect on BPH was first described by
Mitchell et al1 in 4 patients undergoing selective PAE to control massive
prostatic bleeding. Elective PAE for BPHwas first described byDeMeritt
et al2 in 2000. Recent studies showed that PAE is an effective alternative
in reducing lower urinary tract symptoms caused by BPH with a favor-
able safety profile.3–7 Supported by the United Kingdom Register of
Prostate Embolization study,3 the National Institute for Health and Care
Excellence in the United Kingdom approved PAE for treatment of BPH
in their updated guidelines.8
Nevertheless, there is still uncertainty on which patients profit
most from PAE and which patients should be offered other treatment
strategies. There are few studies analyzing imaging and clinical patterns,
enabling the prediction of the outcome after PAE such as preprocedural
high prostate gland volume and extent of prostate gland ischemia ob-
served in early postinterventional magnetic resonance imaging (MRI).9–12
As PAE is a technically challenging procedure due to the highly variable
anatomy of the prostatic artery (PA) and considering the often advanced
atherosclerosis in the elderly male population, knowledge of the exact
anatomy andmorphology of the pelvic arteries including the PA is crucial
for safe PAE.13,14
The primary purpose of this study was to evaluate the visibility
of the PA before PAE in patients with BPH using a novel computed to-
mography (CT) protocol that provides 4-dimensional (4D) CT angiog-
raphy information. Using a dynamic instead of static CT angiography
protocol is motivated by the following reasons: with low kV protocols,
the radiation exposure has a similar magnitude; in dynamic scanning,
every vessel can be visualized at local peak opacification removing timing
issues and potentially allowing to save contrast media; the inherent
availability of precontrast information at identical scan setting enables
CT digital subtraction angiography (DSA) techniques for plaque and
bone removal. This approach, which allows generating “timing-
invariate” CTangiography data, has been successfully used for cerebral
and peripheral CTA applications before.15,16 A secondary aim of this
study was to check the feasibility of also extracting quantitative gland




In total, 22 consecutive patients planned to undergo PAE at our in-
stitution from January to November 2018 were included into the study.
All patients were evaluated by board-certified urologists before CT and
were diagnosed with conservative therapy-refractory BPH and the rec-
ommendation of deobstructive surgery. In all patients, a preinterventional
blood drawwith measurements of the prostate-specific antigen was per-
formed. Furthermore, the International Prostate Symptom Score was
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assessed. The studywas approved by the local ethics committee, and in-
formed consent was obtained from all patients.
Prostate Dynamic Computed Tomography
In all patients, preinterventional dynamic CT of the pelvis was
obtained for treatment planning. All scans were performed on a third-gen-
eration dual-sourceCT scanner (SOMATOMForce; SiemensHealthineers,
Forchheim, Germany). Dynamic CT of the pelvis was performed after
the sublingual administration of 2 sprays of nitroglycerin (Isoket;
Schwarz Pharma, Monheim, Germany) using 70 mL of iopromide
(Ultravist 370, 370 mg I/mL; Bayer Schering Pharma, Berlin,
Germany) at 6 mL/s and a 10-second scan delay. Contrast media injec-
tion was followed by a 20-mL saline chaser at 6 mL/s. Scan range was
22.5 cm using the adaptive 4D spiral mode starting in the craniocaudal
direction. Twenty-five scan cycles at a cycle time of 1.5 seconds and a
total scan time of 44 seconds were performed. Tube voltage and current-
time product were set to 70 kVp and 100 mAs, respectively. The scan
was acquired in a single breath-hold. If breath-hold was not possible
for the entire scan, patients were asked to breath superficially until scan
end. Images were reconstructed with a slice width of 1.5 mm and an in-
crement of 1 mm resulting in around 5600 images per study.
For radiation dose estimation, the volume CT dose index (CTDIvol;
mGy) and dose length product (DLP; mGy·cm) from the automatically
generated dose protocols were taken. Effective dose was calculated
using the ICRP 103 updated conversion coefficient for the pelvis
(κ = 0.015 mSv/[mGy·cm]).17–19 Although the coefficient for male pa-
tients is actually considerably lower (0.010),18we chose to use the most
conservative sex-averaged value published.
Image postprocessing was conducted on a standard postprocessing
client server system (syngo.via; Siemens Healthineers, Erlangen,
Germany) using dedicated applications (CT Dynamic Angio and CT
Body Perfusion). Image postprocessing included noise reduction and
automatic motion correction with generation of the following 3 image
sets out of the single dynamic CT acquisition:
1. Temporal maximum intensity projection (MIP) images (syngo.via
CT Dynamic Angio).
2. Four-dimensional CT angiography images including bone and cal-
cium plaque removal (syngo.via Frontier Pelvic DSA). This step uses
the temporal MIP data and precontrast baseline data simultaneously
generated in step 1.
3. Quantitative color-coded perfusion maps of blood flow (BF, mL/
100 mL/min), blood volume (BV, mL/100 mL), mean transit time
(MTT, seconds), and flow extraction product (FE, mL/100 mL/min)
from the same data (syngo.via CT Body Perfusion). Three-dimen-
sional volumes of interest were placed around the whole prostate
and around the right/left prostate lobe separately. Resulting quantita-
tive perfusion parameters were recorded. In addition, the volume of
interest around the whole prostate provided the prostate gland volume
in milliliter.
Prostate Artery Embolization—Cone-Beam CT
Nineteen (86%) of the 22 patients underwent PAEwithin 30 days
after CT. Two patients decided to stay on medical therapy for BPH after
initial workup with CT. One patient showed severe atherosclerotic
changes and elongation of the pelvic arteries on temporal MIP images
and was consequently offered surgical treatment.
Prostate artery embolization was performed in the 19 patients by
the same interventional radiologist (>15 years of experience). All inter-
ventions took place in a fully equipped angiography suite (ARTIS
zeego and ARTIS pheno; Siemens Healthineers, Erlangen, Germany).
Prostate artery embolization was performed in a standardized manner
with a single-sided femoral access with initial DSA with the catheter
placed in the internal iliac artery (40-degree ipsilateral oblique view).
Subsequently, the PAwas superselectively catheterized with placement
of the microcatheter as distally as possible. For confirmation of correct
microcatheter placement and identification of possible collaterals to
other arteries, a cone-beam CTwas performed by hand injection of 1
to 2 mL of 100% iodinated contrast media (Visipaque; GE Healthcare,
Princeton, NJ). Image reconstruction was performed with a syngo X
workplace (Siemens Healthineers, Erlangen, Germany).
For radiation dose estimation, the dose area product (DAP;
Gy·cm2) and fluoroscopy time were documented. The total DAP of
the PAE was documented as well as the DAP for fluoroscopy alone
and cone-beam CT together with DSA. Effective dose was calculated
using a standard conversion coefficient (κ = 0.26 mSv/Gy·cm2).
Image Quality
Quantitative image quality was assessed in temporalMIP images
and in cone-beam CT by calculating the contrast-to-noise ratio (CNR).
To do so, a region of interest was placed in the proximal right internal
iliac artery and in the right iliac muscle in temporal MIP images. In
intraprocedural cone-beam CT, a region of interest was placed in the
PA of both sides and in the obturator muscle on the ipsilateral side, as
the iliac muscle was usually not in the field of view of cone-beam CT.
For cone-beam CT, the mean CNR of the right and left side was used.
The CNR was calculated for both modalities as follows:
TemporalMIP images: CNR = [attenuation (in HU) in the internal
iliac artery – attenuation (in HU) in the iliac muscle] ÷ standard deviation
of attenuation in the iliac muscle.
Cone-beam CT: CNR = [attenuation (in HU) in the PA – attenu-
ation (in HU) in the obturator muscle] ÷ standard deviation of attenua-
tion in the obturator muscle.
Qualitative image quality was assessed using a 4-point Likert
scale rating the visibility of the prostate artery for each pelvic side sep-
arately (1 = PA not visible, 2 = PA only proximally visible; 3 = PAvis-
ible in its complete course to the prostate without intraparenchymal
branches; 4 = PA visible with intraparenchymal branches). A visibility
score of 2 or higher was defined as being diagnostic. With a visibility
score of 2, the iliac arteries are depicted sufficiently to identify exclu-
sion criteria for PAE. In addition, the origin of the PA is identified that
simplifies superselective catheterization during PAE. The PA was
assessed in 4D-CT angiography after bone removal and cone-beam
CT using the same criteria. Prostatic artery anatomy was classified in
4D-CT angiography according to de Assis et al.20
Statistical Analysis
For descriptive data, mean values and standard deviations are
provided. Continuous variables were compared using the independent
2-sample t test or paired t test, respectively. Categorical variables
were compared using the χ2 test. All statistical analyses were per-
formed with commercially available software (SPSS Statistics v. 23;
IBM, Chicago, IL). Statistical significance was defined as a 2-tailed
P value below 0.05.
RESULTS
Twenty-two patients (44 pelvic sides) were included in the study.
Their mean age was 67 ± 7 years, the mean body mass index was
25.7 ± 3.1 kg/m2, the mean prostate volume was 87 mL (range,
41–196 mL), the mean prostate-specific antigen was 3.6 ± 2.3 ng/mL,
and the mean International Prostate Symptom Score was 22.8 (range,
9–34; Table 1).
Radiation Doses
The average CTDIvol, DLP, and effective dose of CT were
36.6 ± 7.9 mGy, 756.6 ± 168.8 mGy·cm, and 11.3 ± 2.5 mSv, respectively.
Kobe et al Investigative Radiology • Volume 00, Number 00, Month 2019
2 www.investigativeradiology.com © 2019 Wolters Kluwer Health, Inc. All rights reserved.
                                            Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.                                               
                                 This paper can be cited using the date of access and the unique DOI number which can be found in the footnotes.
The average total DAP,DAP (only fluoroscopy), DAP (DSA+ cone-
beam CT), and the effective dose of the PAE procedure were
415.4 ± 208.1 Gy·cm2, 105 ± 67.6 Gy·cm2, 310.5 ± 148.7 Gy·cm2,
and 108 ± 54.1 mSv, respectively. The mean overall fluoroscopy time
was 33.2 ± 15.1 minutes (Table 2). Seventy-six percent of the overall
radiation dose was attributed to DSA and cone-beam CT.
Image Quality and Anatomy
According to de Assis et al,20 type I anatomy of the PAwas pres-
ent in 34.1%, type II in 22.7%, type III in 6.8%, type IV in 31.8%, and
type V in 4.6%.
The CNR in pelvic arteries was significantly higher in cone-beam
CT (69.1 ± 26.9) than on temporal MIP images (44.8 ± 19, P < 0.01).
The mean visibility score of the PA in 4D-CT angiography im-
ages was 3.6 ± 0.6. A visibility score of 4 was achieved in 57% of
PA. In 41% of cases, a score of 3 was achieved. All 4D-CTangiography
images were diagnostic with one PA being identified only proximally
(visibility score 2) due to unilateral hip prosthesis. In the same patient,
cone-beam CT had a visibility score of 3 due to beam-hardening arti-
facts. All other PAwere scored with a visibility score of 4 (mean value,
3.97 ± 0.2) in cone-beam CT, being significantly higher than in 4D-CT
angiography images (P < 0.001; Table 2). Figure 1 shows 2 scans with a
visibility score of 4 in 4D-CT angiography, temporal MIP images, and
cone-beam CT. Figure 2 and Figure 3 illustrate intraprocedural DSA,
4D-CT angiography, and 3-dimensional cinematic rendering images.
In 2 pelvic sides (4.5%), collaterals of the PA to the penile dorsal
artery and superior vesical artery were seen on cone-beam CT needing
superselective catheterization and microcoil placement to avoid nontar-
get embolization. Only the collateral to the superior vesical artery was
also detectable on 4D-CT angiography. Furthermore, 2 pelvic sides
showed tiny collaterals to the rectal artery with no change in treatment
strategy. These collaterals were only seen in intraprocedural cone-beam
CT and were not detectable on 4D-CT angiography even in retrospect.
CT Perfusion Analysis
In all but 1 patient (with unilateral hip prosthesis), quantitative
CT perfusion analysis was feasible. The mean values for BF, BV,
MTT, and FE product were 27.9 ± 12.5 mL/100 mL/min,
2.0 ± 0.8 mL/100 mL, 4.5 ± 0.5 second, and 12.6 ± 5.4 mL/100 mL/
min, respectively.We frequently observed focal hyperintensities (Fig. 4).
The distribution of the global mean values was approximately normally
distributed (narrower for BF) with one outlier on the upper end. In 60%
of the patients, the difference between the lobes was greater than 5%; in
40% of the patients, it was greater than 10% (Table 3 and Fig. 5).
DISCUSSION
The present study introduces a novel dynamic CT protocol of the
pelvis to determine the vascular anatomy including the PA and which
provides additional quantitative information about the perfusion of the
prostate gland.
Computed tomography angiography before PAE is performed in
several institutions given its ability to depict pelvic vessels including
variants and atherosclerotic changes, which is essential for treatment
planning.13,14 Furthermore, patients with unfavorable anatomy can be
excluded upfront and may be offered other treatment strategies. Tortuos-
ity or stenosis of the pelvic arteries and its branches as well as excessive
atherosclerosis are such exclusion criteria. Another reason to perform
preprocedural CT angiography is radiation dose reduction during PAE.
Mean fluoroscopy times for PAE range from 18 to 86 minutes in the lit-
erature.4,21Both studieswith the highest reported fluoroscopy times (55
and 86 minutes, respectively) did not perform preprocedural CT angi-
ography of the pelvis.22,23 In contrast, the 2 studies with the lowest re-
ported fluoroscopy times (18 and 20 minutes, respectively) performed
CT angiography before PAE for anatomical assessment of the PA,
TABLE 1. Baseline Characteristics
Patients, n 22
Age, mean ± SD, y 67 ± 6.6
BMI, mean ± SD (range), kg/m2 25.7 ± 3.1 (18–33)
IPSS (range) 22.8 (9–34)
PSA, mean ± SD, ng/mL 3.6 ± 2.3
Prostate volume (range), mL 86.9 (41–196)
BMI indicates body mass index; IPSS, International Prostate Symptom Score;
PSA, prostate-specific antigen.
TABLE 2. Radiation Doses and Quantitative as well as Qualitative Image Assessments
4D-CTAngiography Intervention P
Radiation dose
CTDIvol, mGy 36.6 ± 7.9
DLP, mGy·cm 756.6 ± 168.8
Total DAP, Gy·cm2 415.4 ± 208.1
DAP (fluoroscopy), Gy·cm2 105 ± 67.6
DAP (DSA + cone-beam CT), Gy·cm2 310.5 ± 148.7
Fluoroscopy time, min 33.2 ± 15.1
Effective dose, mSv 11.3 ± 2.5* 108 ± 54.1† <0.001
4D-CTAngiography Cone-Beam CT
Quantitative image assessment
Contrast-to-noise ratio 44.8 ± 19 69.1 ± 26.9 0.002
Qualitative image assessment
PAvisibility score 3.6 ± 0.6 3.97 ± 0.2 <0.001
Visibility of collaterals (needing coil embolization), % 50 100
*Conversion coefficient = 0.015 mSv/(mGy·cm).
†Conversion coefficient = 0.26 mSv/Gy·cm2.
CTDIvol indicates volume CT dose index; DLP, dose length product; DAP, dose area product; PA, prostatic artery.
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which is most probably the result of faster superselective catheterization
of the PA.24,25 The current study observed a mean fluoroscopy time of
33 minutes, which is at the lower published end.
Despite multiple scan cycles necessary (25 in total), the intro-
duced CT protocol had a DLP of only 760 mGy·cm, which is at the
lower range of previously published values from 800 to 1200 mGy·cm
FIGURE 1. Preprocedural imaging of the prostate gland with the novel CT protocol compared with intraprocedural cone-beam CT. Panels A and D and
panels B and E show the prostate artery (black arrows) with intraparenchymal branches (white arrows) in temporalMIP images and 4D-CT angiography
in a 70-year-old patient with benign prostatic hyperplasia, respectively. Note the ability of bone and calcium removal in 4D-CT angiography (B and E)with
complete removal of all phleboliths (dashed arrows) around the PA. Panels C and F show the corresponding artery (black arrows) and branches (white
arrows) depicted by intraprocedural cone-beam CT.
FIGURE 2. Intraprocedural digital subtraction angiography of the right pelvis (catheter placed in the internal iliac artery; ipsilateral oblique 40-degree
view) depicting the right prostatic artery (white arrow; A). Four-dimensional CT angiography after bone subtraction (B) and 3D cinematic rendering
image (C) of the right pelvic arterial anatomy with illustration of the prostatic artery (white arrow). Intraprostatic branches are seen with both modalities
(white star).
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for conventional CT angiography of the pelvis.13,14,26 This is mainly
due to the fact that the CT scanner used herein is able to acquire data
with a low tube voltage of 70 kVp (at a tube current-time product of
100 mAs). Low kilovoltage scanning goes along with low radiation
doses,27 and additionally results in an increase in attenuation of contrast
media due to scanning closer to the k-edge (33.2 keV) of iodine.28Con-
sequently, an increase in CNR is achieved by low tube voltage scanning.
Despite the high natural attenuation of the hip joints, the CT protocol
resulted in diagnostic images enabling the correct localization of the
PA origin in all patients and sides, and depicted the complete course
of the PA to the prostate in almost all (mean visibility score of 3.6). This
excellent visualization of the pelvic arteries including the PA is the result of
fusion of multiple arterial time points resulting in a single time-resolved,
temporal MIP with low image noise. The latter is achieved by spatiotem-
poral, frequency-depending multiband filtering resulting in increased
CNR at a lower radiation dose. In addition, in the pelvis, there is no issue
withmovement artifacts further improving image quality. Another advan-
tage of this protocolwith a total scan time of 44 seconds—comparedwith
a single-phase CT angiography acquisition—is elimination of timing
problems for ideal enhancement of the pelvic arteries. This might also
explain that at similar dose values, only 70 mL of contrast media were
required, this is about half of what has been used for standard CTangi-
ography (120 to 150mL).14,26 Furthermore, the native baseline scan en-
ables optimal bone and calcium removal in image postprocessing
resulting in 4D-CT angiography images with highly accurate depiction
even of the distal, intraprostatic branches of the PA. So far, there is only
FIGURE 3. Intraprocedural digital subtraction angiography of the left pelvis (catheter placed in the internal iliac artery; ipsilateral oblique 40-degree view)
depicting the left prostatic artery (white arrow; A). Four-dimensional CT angiography after bone subtraction (B) of the left pelvic arterial anatomy with
illustration of the prostatic artery (white arrow). Intraprostatic branches are seen with both modalities (white star). Axial temporal MIP image (C) at the
level of the dashed line depicted in panel B shows a calcium plaque (dashed arrow) in the internal iliac artery. Four-dimensional CT angiography image
(D) shows removal of the calcium plaque (dashed arrow) after postprocessing enabled by the native baseline scan.
FIGURE 4. Postprocessed images of the prostate gland from perfusion CT. A volume of interest is placed around the entire prostate (VOI 1) and another
volume of interest is placed around the right and left prostatic lobe (VOI 2/VOI 3), respectively. Quantitative CT perfusion results are depicted in (E).
Color-coded images of blood flow, blood volume, flow extraction product, and mean transit time are seen in panels A to D.
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one study in the literature analyzing the visibility of the PA with CT,
reporting avisualization of intraparenchymal PA branches in 19% of cases
by single phase CT angiography.26 In contrast, with our CT protocol, we
were able to visualize intraparenchymal branches in 57% of cases.
Vessel CNR in our studywas still significantly higher in cone-beam
CT compared with the proposed CT protocol due to direct superselective
injection of contrast media with no dilution effects. But it is noteworthy,
and also due to low kV usage, that CNR for intravenous injection was
only 35% lower (45 vs 69) than for intra-arterial injection.
Intraprocedural cone-beam CT is considered crucial before PAE
to avoid nontarget embolization due to collaterals to other arteries. Given
the distal placement of the microcatheter in cone-beam CT, a mean visibil-
ity score of the PA of 3.97 was achieved, almost always depicting
intraparenchymal branches and also visualizing collaterals of the PA. Col-
laterals of the PA to other arteries are described in 23% to 50% of
PA.29–31 In our study, 2 PA showed collaterals needing coiling before em-
bolization. Only one of these collaterals (50%) was detected also in prepro-
cedural CT, which is consistent with Maclean et al14 who found a
sensitivity of collateral detection with CTangiography of only 59%. Given
the relatively low sensitivity of distal collateral detection in both conven-
tional CT angiography and in the proposed dynamic pelvic CT protocol,
it is still crucial to perform intraprocedural cone-beam CT for safe PAE.
TABLE 3. Prostate Perfusion Analysis
Whole Prostate Lobe Difference (Range), %
Blood flow, mL/100 mL/min 27.9 ± 12.5 11 (1–33)
Blood volume, mL/100 mL 2.0 ± 0.8 11 (0–33)
Flow extraction product, mL/100 mL/min 12.6 ± 5.4 14 (1–35)
Mean transit time, s 4.5 ± 0.5 3 (0–6)
FIGURE 5. Distribution of blood flow (A) and flow extraction product (B) for thewhole prostate. The dashed line is the corresponding normal distribution;
there is one outlier on the upper end. Distribution of the absolute difference between left and right lobe for blood flow (C) and flow extraction product
(D). Sixty percent of the patients have a difference greater than 5%, 40% greater than 10% between lobes.
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Despite its acknowledged efficacy in relieve of symptoms caused
by BPH, there is still uncertainty on which patients are best candidates for
PAE. There are studies showing that the initial prostate gland volume
correlates with a favorable clinical outcome after PAE.9–11 Neverthe-
less, this was not confirmed by Bagla et al32 who found no differences
in clinical outcome in patients stratified by preprocedural prostate gland
volume. Other studies focused on early postinterventional parameters
and found that the amount of prostate gland ischemia observed in early
postinterventional MRI and prostate-specific antigen level 24 hours after
intervention predicted clinical success of PAE.12,33
None of these studies took functional parameters such as perfusion
data into account. One recent study by Brook et al34 studied the influence
of embolic size on therapy response in a dogmodel. An increase of time to
maximal perfusion intensity of the prostate right after PAE, assessed by
dynamic contrast-enhanced MRI, showed a higher decrease in prostate
volume. So far, only one study evaluated the vascularization of the prostate
before embolization and found that increased vascularization was associ-
ated with favorable outcome after PAE.35 However, this study analyzed
vascularization of the prostate only subjectively during intervention
by DSA, which may suffer from subjectivity and limited reproducibil-
ity. Here, quantification of tissue perfusion with CT may be useful.
There is very limited literature on perfusion in BPH, with most
studies dealing with prostate cancer.36 Our injection protocol deviates
slightly from typical oncological perfusion applications, because we
injected for 12 seconds instead of typically not more than 10 seconds.37
This was done to achieve sufficient peak enhancement for CTangiogra-
phy image generation. Still, we believe that this does not negatively influ-
ence perfusion results as, unlike cancer, normal and benign hyperplastic
tissue does not have increased vascularity. Interestingly, there is one dy-
namic contrast-enhanced MRI study in BPH that reported plasma flow
and Ktrans values (mL/100 mL/min) of 21 and 10, respectively, for the
central gland and of 16 and 6, respectively, for the peripheral zone.38
When converting our BF and FE values to plasma units (assuming a he-
matocrit level of 0.4), we obtain flow and Ktrans values of 17 and 8 mL/
100 mL/min, respectively, for the whole prostate. This is in very good
agreement with the MRI study.38We can only speculate if the frequently
observed focal hyperintensities might be related to the nodular nature of
BPH, as we neither had a morphological reference nor outcome data. But
as demonstrated in our study, perfusion analysis of the prostate seems
feasible with CT providing quantitative information, which might be
predictive for therapy response as shown in previous studies predicting
the response to radioembolization in liver metastases39 and response to
angiogenesis inhibitors in metastatic renal cell carcinoma,40 using per-
fusion CT performed before radio/chemotherapy.
Wemust acknowledge some study limitations. First, we included
only a small sample size with 22 patients. Moreover, we have (so far) no
outcome data available proving the usefulness of perfusion CT imaging
as an outcome predictor for pretreatment workup. This needs to be in-
vestigated in future prospective trials. Another limitation of our proto-
col might be the image quality at a low tube voltage (70 kVp) in
obese patients. We did not encounter any problems with image quality
at a fairly normal BMI distribution (mean, 25.7 ± 3.1 kg/m2) in this
study. Use of higher tube voltages might overcome problems in obese
patients, with the downside of resulting in higher radiation doses.
In conclusion, our study introduces a novel CT protocol of the
pelvis enabling the visualization of the PA for treatment planning with
temporal MIP images and 4D-CTangiography at a reasonable radiation
dose and contrast volume. Whether the additional quantitative perfu-
sion information of the prostate gland can serve as a potential outcome
predictor after PAE requires further studies.
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